SUPN News and Press, Supernus Pharmaceuticals Inc. From 05/09/22

First quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021 First quarter 2022 net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectively First quarter 2022 GAAP operating income of $2.0 million; first ...

Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to announce Q1 earnings results on Monday, May 9th, after market close. The consensus EPS Estimate is $0.45 (+225.0% Y/Y) and the consensus Revenue Estimate is $150.47M (+679.2% Y/Y). Over the last 1 year, SUPN has beaten EPS estimates 75% o...

ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report finan...

Supernus Pharmaceuticals (NASDAQ:SUPN), a pharma company focused on CNS disorders, is trading ~9% higher in the pre-market Monday after the firm announced that the U.S. Food and Drug Administration (FDA) expanded the indication for its ADHD therapy Qelbree. Accordingly, the drug, al...

First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on de...

Supernus Pharmaceuticals press release (NASDAQ:SUPN): Q4 GAAP EPS of $0.04 misses by $0.20. Revenue of $159.05M (+10.8% Y/Y) in-line. 2022 Guidance: Total revenues $640 - $680M, Combined R&D and SG&A expenses $460 - $490M, Operating earnings $20 - $40M, Effective tax rate 25% - 2...

Annual Report on Form 10-K filed on April 13, 2022 Reiterates full year 2022 financial guidance provided on February 28, 2022 and reiterated on April 4, 2022 ROCKVILLE, Md., April 13, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutica...

Biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases Supernus Pharmaceuticals (NASDAQ:SUPN) reiterates FY2022 financial guidance initially announced on February 28, 2022. Expects total revenues between $640...

Annual Report on Form 10-K for fiscal year ended December 31, 2021 to be filed in the near term Reiterates full year 2022 financial guidance provided on February 28, 2022 ROCKVILLE, Md., April 04, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharm...

Supernus' Q4 earnings provide a first peek at a brand new Supernus. Qelbree is the big wildcard for Supernus investors; management has big dreams. Supernus' newly acquired and developing PD franchise will be important drivers of overall performance. For further details see: ...